Dr. Tahereh Ghorbani Rodriguez, M.D
Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $285.00 | 1 | 65.9% |
| Food and Beverage | $80.79 | 2 | 18.7% |
| Gift | $42.50 | 1 | 9.8% |
| Education | $24.47 | 1 | 5.7% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $285.00 | 1 | $0 (2023) |
| Novo Nordisk Inc | $80.79 | 2 | $0 (2019) |
| Mannkind Corporation | $42.50 | 1 | $0 (2024) |
| Radius Health, Inc. | $24.47 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $42.50 | 1 | Mannkind Corporation ($42.50) |
| 2023 | $285.00 | 1 | Eli Lilly and Company ($285.00) |
| 2020 | $24.47 | 1 | Radius Health, Inc. ($24.47) |
| 2019 | $44.94 | 1 | Novo Nordisk Inc ($44.94) |
| 2018 | $35.85 | 1 | Novo Nordisk Inc ($35.85) |
All Payment Transactions
5 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/05/2024 | Mannkind Corporation | AFREZZA (Drug) | Gift | In-kind items and services | $42.50 | General |
| Category: DIABETES MEDICINE | ||||||
| 01/31/2023 | Eli Lilly and Company | — | — | In-kind items and services | $285.00 | Research |
| Study: EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT- RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-1) | ||||||
| 10/13/2020 | Radius Health, Inc. | Tymlos (Biological) | Education | In-kind items and services | $24.47 | General |
| Category: Endocrinology | ||||||
| 04/11/2019 | Novo Nordisk Inc | Saxenda (Drug) | Food and Beverage | In-kind items and services | $44.94 | General |
| Category: Obesity | ||||||
| 05/19/2018 | Novo Nordisk Inc | Victoza (Drug) | Food and Beverage | In-kind items and services | $35.85 | General |
| Category: Diabetes | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT- RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-1) | Eli Lilly and Company | $285.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 294 | 378 | $114,841 | $24,136 |
| 2022 | 5 | 296 | 379 | $116,177 | $24,978 |
| 2021 | 6 | 217 | 237 | $76,919 | $20,202 |
| 2020 | 3 | 105 | 138 | $26,015 | $8,228 |
All Medicare Procedures & Services
19 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 157 | 224 | $63,013 | $14,588 | 23.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 80 | 80 | $36,439 | $6,794 | 18.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 21 | 22 | $4,213 | $1,051 | 25.0% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2023 | 20 | 35 | $4,477 | $867.24 | 19.4% |
| 10005 | Fine needle aspiration biopsy using ultrasound guidance, first growth | Office | 2023 | 16 | 17 | $6,699 | $835.20 | 12.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 151 | 216 | $60,780 | $14,646 | 24.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 65 | 65 | $32,475 | $5,370 | 16.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 30 | 34 | $13,192 | $2,868 | 21.7% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2022 | 30 | 42 | $5,418 | $1,115 | 20.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 20 | 22 | $4,312 | $979.16 | 22.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 69 | 73 | $21,124 | $5,420 | 25.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 36 | 41 | $15,908 | $4,564 | 28.7% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 40 | 40 | $19,121 | $4,239 | 22.2% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2021 | 46 | 56 | $11,480 | $3,691 | 32.2% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 13 | 13 | $7,480 | $1,906 | 25.5% |
| 95251 | Ambulatory continuous glucose (sugar) including interpretation and report for a minimum of 72 hours | Office | 2021 | 13 | 14 | $1,806 | $382.06 | 21.2% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 59 | 84 | $17,220 | $5,813 | 33.8% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2020 | 29 | 35 | $4,900 | $1,547 | 31.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 17 | 19 | $3,895 | $868.37 | 22.3% |
About Dr. Tahereh Ghorbani Rodriguez, M.D
Dr. Tahereh Ghorbani Rodriguez, M.D is a Endocrinology, Diabetes & Metabolism healthcare provider based in Chapel Hill, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/04/2007. The National Provider Identifier (NPI) number assigned to this provider is 1285828186.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Tahereh Ghorbani Rodriguez, M.D has received a total of $432.76 in payments from pharmaceutical and medical device companies, with $42.50 received in 2024. These payments were reported across 5 transactions from 4 companies. The most common payment nature is "" ($285.00).
As a Medicare-enrolled provider, Ghorbani Rodriguez has provided services to 912 Medicare beneficiaries, totaling 1,132 services with total Medicare billing of $77,543. Data is available for 4 years (2020–2023), covering 19 distinct procedure/service records.
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism|Endocrinology, Diabetes & Metabolism
- Location Chapel Hill, NC
- Active Since 09/04/2007
- Last Updated 05/14/2023
- Taxonomy Code 207RE0101X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1285828186
Products in Payments
- Saxenda (Drug) $44.94
- AFREZZA (Drug) $42.50
- Victoza (Drug) $35.85
- Tymlos (Biological) $24.47
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Endocrinology, Diabetes & Metabolism Doctors in Chapel Hill
Dr. John Buse, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $569,574
Dr. Atil Kargi, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $74,990
Sadia Ejaz, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $14,296
Dr. Rebecca Vitale, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $5,000
Dr. Janet Rubin, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $3,818
Karla Pou, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $478.70